ACM
TSHA icon

ADAR1 Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

ADAR1 Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3M Buy
2,979,429
+483,620
+19% +$2.25M 0.78% 29
2025
Q4 		$13.7M Sell
2,495,809
-339,871
-12% -$1.65M 1.01% 24
2025
Q3 		$9.27M Sell
2,835,680
-174,190
-6% -$493K 0.87% 26
2025
Q2 		$6.95M Buy
3,009,870
+1,943,561
+182% +$4.22M 1.07% 25
2025
Q1 		$1.48M Buy
1,066,309
+888,602
+500% +$1.49M 0.28% 66
2024
Q4 		$307K Sell
177,707
-73,693
-29% -$153K 0.06% 133
2024
Q3 		$505K Buy
251,400
+600
+0.2% +$1.32K 0.08% 113
2024
Q2 		$562K Buy
250,800
+207,300
+477% +$603K 0.11% 92
2024
Q1 		$125K Sell
43,500
-165,500
-79% -$345K 0.03% 139
2023
Q4 		$370K Buy
+209,000
New +$417K 0.13% 67

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ADAR1 Capital Management's TSHA Position: Q1 2026 in Review

ADAR1 Capital Management increased its Taysha Gene Therapies (TSHA) stake by 19% in Q1 2026, buying an estimated $2.25M and bringing the position to 2,979,429 shares worth $13.3M. The position accounts for 0.78% of the portfolio, ranked #29.

ADAR1 Capital Management first reported a position in TSHA in Q4 2023 and has held it in 10 quarters since. The position peaked at $13.7M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • ADAR1 Capital Management held 2,979,429 shares of Taysha Gene Therapies worth $13.3M as of Q1 2026.
  • ADAR1 Capital Management bought 483,620 Taysha Gene Therapies shares in Q1 2026, an estimated $2.25M.
  • Taysha Gene Therapies made up 0.78% of ADAR1 Capital Management's portfolio in Q1 2026, its #29 holding.
  • ADAR1 Capital Management first reported a position in Taysha Gene Therapies in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Taysha Gene Therapies position peaked at $13.7M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.